Back to top
more

Avanos Medical (AVNS)

(Delayed Data from NYSE)

$18.10 USD

18.10
133,303

+0.25 (1.40%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $18.09 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.

Why Is Integra (IART) Down 4% Since Last Earnings Report?

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Avanos (AVNS) Q4 Earnings Lag Estimates, Margins Contract

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall fourth-quarter results reflect soft performances.

New Strong Sell Stocks for January 16th

AMFPF, ADI and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 16, 2024.

New Strong Sell Stocks for January 12th

AIR, AVNS and BP have been added to the Zacks Rank #5 (Strong Sell) List on January 12, 2024.

New Strong Sell Stocks for January 9th

AIR, AMSF and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 9, 2024.

Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales

Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.

Avanos Medical (AVNS) Up 0.1% Since Last Earnings Report: Can It Continue?

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Avanos (AVNS) Q3 Earnings Top Estimates, Margins Contract

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall third-quarter results reflect soft performances.

What's in Store for Cardinal Health (CAH) in Q1 Earnings?

Cardinal Health's (CAH) first-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.

Why Avanos (AVNS) Might Surprise This Earnings Season

Avanos (AVNS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Stryker (SYK) to Report Q3 Earnings: Is a Beat in Store?

Stryker's (SYK) third-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

Cencora (COR) to Report Q4 Earnings: What's in the Cards?

Cencora's (COR) fiscal fourth-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

DENTSPLY SIRONA's (XRAY) third-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?

Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

McKesson (MCK) to Report Q2 Earnings: What's in the Cards?

McKesson's (MCK) second-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Revvity (RVTY) to Report Q3 Earnings: What's in the Cards?

Revvity's (RVTY) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

Avanos Medical (AVNS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Avanos Medical (AVNS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?

DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.

Avanos (AVNS) Q2 Earnings and Revenues Fall Shy of Estimates

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall second-quarter results reflect soft performances.

Avanos Medical (AVNS) Q2 Earnings and Revenues Lag Estimates

Avanos Medical (AVNS) delivered earnings and revenue surprises of -29.41% and 12.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?

AmerisourceBergen's (ABC) fiscal third-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

Stryker's (SYK) second-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

AVNS vs. EW: Which Stock Is the Better Value Option?

AVNS vs. EW: Which Stock Is the Better Value Option?

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.